Floor & Decor Hldgs에 대한 매도 수량은 투자자에게 Floor & Decor Hldgs의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Floor & Decor Hldgs (NYSE:FND) 주식, 공매도 수량 보고

Floor & Decor Hldgs

Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site.

Large Cap

News

Movers

Trading Ideas

AKAM

FSLR

MELI

MRNA

PINS

지난주 카멀라 해리스가 2024년 미국 대선에서 패배하면서 다음 10개의 대형 주식이 가장 저조한 성과를 보였다. 

카멀라 해리스 대선 패배 주간(11월 4~8일) 대폭 하락한 대형주 10종목

ALNY

COIN

MBLY

RIVN

SMMT

STLA

FLSR

이들 11개 대형주들은 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?1. 휴마나(NYSE:HUM)가 별 등급의 2025년 실적 하락과 이것이 2026년 품질 보너스 지급에 어떤 영향을 미칠지에 대해 투자자들에게 업데이트한 후 주가는 24.89% 하락했다. 몇몇 분석가들은 주가 예측을 낮췄다.

코인베이스, 나이키 및 모더나는 지난주 최악의 성과를 보인 11개 대형주 중 일부 (9월 30일-10월 4일)

Equities

Markets

AAPL

SNOW

TMUS

ULTA

전설적인 투자자 워런 버핏은 보유 애플(NASDAQ:AAPL) 지분의 상당한 감소를 포함하여 2분기에 버크셔 해서웨이(NYSE:BRK) (NYSE:BRK)의 상당한 주식 매각을 공개했다.

워런 버핏은 여전히 ​​애플 4억 주를 보유, 울타 뷰티와 하이코에 대한 새로운 투자 공개

Floor & Decor Holdings, Inc. Common Stock

Floor & Decor Holdings Inc

Schwab Fundamental U.S. Small Company ETF

Schwab Fundamental U.S. Broad Market ETF

Schwab Fundamental International Small Equity ETF

Schwab Fundamental Emerging Markets Equity ETF

Schwab Fundamental International Equity ETF

Fund.com Inc

FVI FND VAL/INMBL ADR by FVI Fondo Valores Inmobiliarios

FVI Fondo De Valores Inmobiliarios SACA

FRIENDTIMES INC by FRIENDTIMES INC.

Schwab Fundamental U.S. Large Company ETF

FNDZ

Piper Sandler analyst Alexander Goldfarb maintains Hudson Pacific Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) with a Neutral and lowers the price target from $5 to $4.5.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Hudson Pacific Properties, Lowers Price Target to $4.5

RBC Capital analyst Logan Reich reiterates Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Outperform and maintains $115 price target.

Reiteration

SBUX

RBC Capital Reiterates Outperform on Starbucks, Maintains $115 Price Target

Zai Lab Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) shares are trading higher by 3.45% to $27.59 during Friday&#8217;s session. The company priced a $200 million public offering of 7,843,137 shares at <a href="https://www.benzinga.com/pressreleases/24/11/b41997659/zai-lab-announces-pricing-of-public-offering-of-american-depositary-shares">$25.50 per ADS</a>.
The offering is expected to close on November 18, subject to customary conditions. The company has also granted underwriters a 30-day option to purchase an additional 1,176,470 ADSs. 
Net proceeds will be used for general corporate purposes. Goldman Sachs, Jefferies and Leerink Partners are the joint book-running managers for the offering.
Read Also: <a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a>
<h2 class="wp-block-heading">How To Buy ZLAB Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instruments.
For example, in Zai Lab&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ZLAB has a 52-week high of $36.50 and a 52-week low of $13.48.

ZLAB

Why Zai Lab (ZLAB) Stock Is Trading Higher

Raymond James analyst Stephen Boland maintains Pollard Banknote (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PBL#TSX">PBL</a>) with a Outperform and raises the price target from C$44 to C$46.

TSX:PBL

Raymond James Maintains Outperform on Pollard Banknote, Raises Price Target to C$46

AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares are moving lower on Friday after the company reported worse-than-expected 2024 third-quarter fiscal earnings after the bell <a href="https://www.benzinga.com//node/41994523">on Thursday</a>.
What Happened: AST SpaceMobile shares fell about 13% after the company released earnings on Thursday. The earnings report included a loss of $1.10 per share, missing analyst estimates of a loss of 20 cents per share.
Furthermore, the company reported sales of $1.10 million, missing analyst estimates of $24.13 million. AST SpaceMobile reported other key pieces of financial data, including adjusted operating expenses of $45.3 million.
The company incurred about $374 million of gross capitalized property and equipment costs. It also reported $518.9 million in cash, cash equivalents and restricted cash. 
Stepping back from finances, the company announced several key agreements, such as launch service agreements with Blue Origin for launches in 2025 and 2026. These agreements will enable the orbital deployment of up to 60 Block 2 BlueBird satellites.
The company&#8217;s coverage will initially target key markets, including the U.S., Japan, and Europe.
Additionally, the company achieved initial validation of its AST5000 ASIC chip, with the necessary infrastructure in place for commissioning in 2025. The combination of the new chip and the larger Block 2 array will support enhanced data transmission.
&#8220;We achieved many significant milestones in the quarter and continue our momentum with several key pieces now in place,&#8221; said Abel Avellan, founder, chairman and CEO of AST SpaceMobile. 
&#8220;With the first five BlueBird satellites successfully unfolded and entering initial operations, our business is progressing according to plan. We&#8217;ve advanced our strategy across multiple efforts including progress on securing orbital launch capacity, growing our manufacturing capability, and expanding our customer ecosystem.&#8221;
Following the earnings report, UBS analyst Christopher Schoell maintained a Buy rating on AST SpaceMobile and raised the price target from&nbsp;$30&nbsp;to&nbsp;$31.
Related Link: <a href="https://www.benzinga.com/24/11/41961161/musk-ramaswamy-headed-doge-department-will-be-an-incredibly-challenging-endeavor-says-ted-cruzshares-this-piece-o">Ted Cruz Says Running DOGE Won&#8217;t Be A Cake Walk, Offers Reading Advice To Elon Musk</a>
ASTS Price Action: At the time of publication, AST SpaceMobile shares are moving 13.8% lower at $23.11, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Company

ASTS

What's Going On With AST SpaceMobile Stock Friday?

Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) stock is moving lower Friday after Warren Buffet&#8216;s Berkshire Hathaway <a href="https://www.benzinga.com/markets/equities/24/11/41993666/warren-buffetts-berkshire-hathaway-slashes-apple-bofa-holdings-adds-dominos-pizza-in-q3">cut its position in the company. </a>
What To Know: Buffet&#8217;s Berkshire Hathaway cut nearly all of its position in the beauty brand, according to Berkshire&#8217;s latest 13F filing.
Berkshire initially reported holding 690,106 shares in Ulta in an August filing. The latest 13F filing, released Thursday, shows its position has been reduced to 24,203 shares, a 96% cut.
The filing also indicates new positions in Domino&#8217;s Pizza Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) and Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>). Berkshire acquired 1,277,256 shares of Domino&#8217;s, valued at approximately $549 million, and 404,057 shares of Pool Corp, worth about $152 million.
Furthermore, the filing shows that Berkshire continued to reduce its stake in Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>). The August filing represents the company&#8217;s holdings as of June 30, while Thursday&#8217;s filing reports Berkshire&#8217;s holdings as of Sept. 30.
How To Buy Ulta Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Ulta Beauty's case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a>
ULTA Price Action: At the time of writing, Ulta stock is moving 2.39% lower at $373.24, Domino&#8217;s shares are moving 2.07% higher at $444.98, Pool stock is moving 2.52% higher at $366.51, Bank of America shares are trading 0.86% higher at $46.29, and Apple stock is moving 1.45% lower at $244.88 per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Wikimedia Commons

POOL

What's Going On With Ulta Beauty Shares Friday?

Spectrum Brands Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading lower on Friday.</a>
The company reported fourth-quarter adjusted earnings per share of 97 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42004018/spectrum-brands-holdings-reports-fiscal-2024-fourth-quarter" rel="noreferrer noopener">missing the street view of $1.07</a>. Quarterly revenues were $773.7 million (+4.5%), beating the analyst consensus of $747.51 million.
Gross profit surged 17.8% to $288 million. Gross profit and margin increased due to productivity improvements, operational efficiencies, and inventory actions in the prior year, partially offset by ocean freight inflation.
Adjusted EBITDA decreased $42.6 million, driven by $32.5 million of lower investment income and $25.9 million of increased brand-focused investments, offset by gross profit improvements.
As of the fiscal year-end, the company reported a cash balance of $369 million and total liquidity of $860 million, including undrawn capacity on its cash flow revolver.
It had $578 million in outstanding debt, consisting of $496 million in senior unsecured notes and around $82 million in finance lease obligations, resulting in a net debt of approximately $209 million.
Outlook: Spectrum Brands expects low single-digit growth in reported net sales in fiscal 2025 and adjusted EBITDA to increase by mid to high single-digits. Adjusted free cash flow is expected to be approximately<a href="https://www.benzinga.com/calendars/guidance"> 50% of adjusted EBITDA.</a>
The company continues to target a long-term net leverage ratio of 2.0 &#8211; 2.5 times.
&#8220;I am excited about the upcoming year. Our focus during fiscal 2025 will be to continue the momentum we built in fiscal 2024 by investing in our brands to drive long-term growth, in innovation to expand core and adjacent categories, and in our operations to drive further cost improvement, quality and safety,&#8221; said David Maura, Chairman and Chief Executive Officer of Spectrum Brands.
Price Action: SPB shares are trading lower by 4.78% to $89.38&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42012197/totalenergies-joins-bp-equinor-and-shell-in-500m-drive-for-global-energy-access\" target="_blank" rel="noreferrer noopener">TotalEnergies Joins BP, Equinor, And Shell In $500M Drive For Global Energy Access</a></li>
</ul>

Earnings

Guidance

General

Spectrum Brands Stock Falls After Q4 Earnings Miss On Lower Investment Income: Details

Raymond James analyst Michael Barth reiterates Enerflex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EFX#TSX">EFX</a>) with a Outperform and raises the price target from C$12 to C$13.75.

TSX:EFX

Raymond James Reiterates Outperform on Enerflex, Raises Price Target to C$13.75

RBC Capital analyst Matthew McKellar reiterates Smurfit WestRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) with a Outperform and maintains $58 price target.

RBC Capital Reiterates Outperform on Smurfit WestRock, Maintains $58 Price Target

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.&#8217;s nomination to lead the&nbsp;Department of <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">Health and Human Services</a>.
Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">debunked this theory</a>.
Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous" rel="noreferrer noopener">being in charge</a>.
Kennedy, who received Trump&#8217;s blessing to &#8220;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics" rel="noreferrer noopener">go wild on health</a>,&#8221; has stated intentions to overhaul various aspects of the federal health agencies.
In a post on social media, Kennedy <a target="_blank" href="https://x.com/RobertKennedyJr/status/1857198805919138235" rel="noreferrer noopener">said</a>, &#8220;Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.&#8221;
On Friday, the World Health Organization also defended vaccines describing them as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill" target="_blank" rel="noreferrer noopener">childhood without them</a>.
European vaccine player stocks declined, including&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">BioNTech SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">in vaccine sales</a>.
COVID-19 vaccine players <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener">Moderna Inc</a><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener"> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">Pfizer Inc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.
Other vaccine players&#8217; stocks that are down include Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Inovio Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>).
Price Action: GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></li>
</ul>
Photo by Vladimka production via Shutterstock

Biotech

Eurozone

Health Care

BNTX

VALN

European And US Vaccine Stocks Are Under Pressure - Here's WHy

WIIM

NDRA

ENDRA Life Sciences shares are trading lower. The company reported Q3 financial results.

Raymond James analyst Stephen Boland maintains CI Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CIX#TSX">CIX</a>) with a Outperform and raises the price target from C$22 to C$27.

TSX:CIX

Raymond James Maintains Outperform on CI Financial, Raises Price Target to C$27

ALRN

Aileron Therapeutics shares are trading lower. The company reported Q3 financial results.

RBC Capital analyst Jimmy Shan maintains Flagship Communities (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MHC#TSX">MHC</a>) with a Outperform and raises the price target from C$19 to C$20.

TSX:MHC

TSX:MHC/U

RBC Capital Maintains Outperform on Flagship Communities, Raises Price Target to C$20

OMGA

Omega Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results and Piper Sandler cut its price target on the stock from $9 to $4.

ALUR

Allurion Technologies shares are trading lower after Chardan Capital downgraded the stock from Buy to Neutral.

BMO Capital analyst Ben Pham maintains Boralex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BLX#TSX">BLX</a>) with a Outperform and lowers the price target from C$46 to C$45.

TSX:BLX

BMO Capital Maintains Outperform on Boralex, Lowers Price Target to C$45

VUZI

Vuzix shares are trading lower after the company reported worse-than-expected Q3 financial results.

Deep-pocketed investors have adopted a bearish approach towards Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TEM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Tempus AI. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 50% bearish. Among these notable options, 6 are puts, totaling $683,586, and 2 are calls, amounting to $99,000.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $55.0 for Tempus AI during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Tempus AI's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tempus AI's whale activity within a strike price range from $30.0 to $55.0 in the last 30 days. 
<h3>Tempus AI 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731687434_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.8</td>
<td>$4.5</td>
<td>$5.4</td>
<td>$45.00</td>
<td>$246.2K</td>
<td align="right">85</td>
<td align="right">500</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.3</td>
<td>$5.0</td>
<td>$5.4</td>
<td>$45.00</td>
<td>$225.7K</td>
<td align="right">85</td>
<td align="right">462</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$4.7</td>
<td>$4.3</td>
<td>$4.7</td>
<td>$52.00</td>
<td>$92.5K</td>
<td align="right">206</td>
<td align="right">200</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$9.2</td>
<td>$7.7</td>
<td>$9.2</td>
<td>$55.00</td>
<td>$63.4K</td>
<td align="right">10</td>
<td align="right">90</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$23.7</td>
<td>$22.0</td>
<td>$23.0</td>
<td>$30.00</td>
<td>$50.6K</td>
<td align="right">0</td>
<td align="right">44</td>
</tr>
</tbody>
</table>

<h3>About Tempus AI</h3>
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
After a thorough review of the options trading surrounding Tempus AI, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Tempus AI</h3>
<ul>
<li>With a trading volume of 572,433, the price of TEM is up by 0.32%, reaching $56.81.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 94 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Tempus AI</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $67.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $70. 
&#x2A; Reflecting concerns, an analyst from Stifel lowers its rating to Hold with a new price target of $65.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Tempus AI with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Behind the Scenes of Tempus AI's Latest Options Trends

Deep-pocketed investors have adopted a bearish approach towards Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TTD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Trade Desk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 19% leaning bullish and 71% bearish. Among these notable options, 11 are puts, totaling $1,047,442, and 10 are calls, amounting to $2,142,826.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $140.0 for Trade Desk during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Trade Desk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Trade Desk's significant trades, within a strike price range of $90.0 to $140.0, over the past month.
<h3>Trade Desk Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731687428_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$34.85</td>
<td>$34.25</td>
<td>$34.4</td>
<td>$90.00</td>
<td>$1.0M</td>
<td align="right">746</td>
<td align="right">301</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.5</td>
<td>$9.45</td>
<td>$9.45</td>
<td>$105.00</td>
<td>$608.5K</td>
<td align="right">16</td>
<td align="right">644</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$32.2</td>
<td>$32.0</td>
<td>$32.0</td>
<td>$92.50</td>
<td>$320.0K</td>
<td align="right">634</td>
<td align="right">100</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$32.8</td>
<td>$31.05</td>
<td>$32.4</td>
<td>$92.50</td>
<td>$181.4K</td>
<td align="right">634</td>
<td align="right">100</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.2</td>
<td>$26.75</td>
<td>$27.09</td>
<td>$115.00</td>
<td>$162.8K</td>
<td align="right">486</td>
<td align="right">60</td>
</tr>
</tbody>
</table>

<h3>About Trade Desk</h3>
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.
<h3>Where Is Trade Desk Standing Right Now?</h3>
<ul>
<li>With a volume of 1,511,116, the price of TTD is down -1.1% at $124.49. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 90 days.</li>
</ul>
<h3>Professional Analyst Ratings for Trade Desk</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $109.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Trade Desk with a target price of $135. 
&#x2A; An analyst from DA Davidson persists with their Buy rating on Trade Desk, maintaining a target price of $134. 
&#x2A; An analyst from New Street Research has revised its rating downward to Sell, adjusting the price target to $86. 
&#x2A; An analyst from Benchmark downgraded its action to Sell with a price target of $57. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Trade Desk with a target price of $135. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Trade Desk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in Trade Desk

Analysts fell to the sidelines weighing in on Brinker International (EAT – Research Report), Floor & Decor Holdings (FND – Research Report) and MGM...

Analysts Offer Insights on Consumer Cyclical Companies: Brinker International (EAT), Floor & Decor Holdings (FND) and MGM Resorts (MGM)

In a report released today, Peter Keith from Piper Sandler maintained a Hold rating on Floor & Decor Holdings (FND – Research Report), with a price...

Floor & Decor Holdings (FND) Gets a Hold from Piper Sandler

In a report released today, Joe Feldman from Telsey Advisory maintained a Hold rating on Floor & Decor Holdings (FND – Research Report), with a pri...

Telsey Advisory Reaffirms Their Hold Rating on Floor & Decor Holdings (FND)

Telsey Advisory analyst Joe Feldman maintained a Hold rating on Floor & Decor Holdings (FND – Research Report) today and set a price target of $95....

Floor & Decor Holdings (FND) Receives a Hold from Telsey Advisory

Baird Q3 2024 Mid Cap Growth Equity Fund Commentary

Baird Q3 2024 Small/Mid Cap Growth Equity Fund Commentary

Wedbush analyst Seth Basham reiterated a Buy rating on Floor & Decor Holdings (FND – Research Report) today and set a price target of $110.00. The ...

Wedbush Reaffirms Their Buy Rating on Floor & Decor Holdings (FND)

Warren Buffett's Berkshire Hathaway disclosed in an SEC filing its holdings as of September 30, 2024. Berkshire's two new buys during the third qua...

Berkshire Hathaway takes new position in Domino's cuts stake in Apple

Buffett's Berkshire Hathaway adds Domino's, exits Floor & Decor: Q3 trades

Berkshire Hathaway (BRK.B), the holding company of legendary investor Warren Buffett, opened new positions in the stocks of Domino's Pizza ($DPZ) a...

Berkshire Hathaway (BRK.B) Opens New Positions in Domino's Pizza and Pool Corp.

AAON

ACLS

ALAB

APPF

APTV

BOOT

BROS

BURL

BWXT

CACI

CASY

CHTR

CSGP

CWAN

CYBR

DLTR

DXCM

EPAM

EXLS

FANG

FIVE

FOUR

ICLR

INSP

IRTC

JKHY

KNSL

LGIH

LSCC

MANH

MEDP

MKTX

MNDY

MPWR

MSCI

NBIX

ONTO

PCOR

PODD

PRCT

RGEN

RXST

SITM

SMPL

TARS

TECH

TREX

VEEV

VNOM

Press Releases

Floor & Decor Announces Grand Opening of Four New Stores Across the U.S.

Floor & Decor Announces Grand Opening of Owings Mills, Maryland Store

Floor & Decor Holdings, Inc. Announces Third Quarter Fiscal 2024 Earnings Conference Call

Floor & Decor Announces Grand Opening of Daytona Beach, Florida Store

Floor & Decor Holdings, Inc. Announces Third Quarter Fiscal 2024 Financial Results

Floor & Decor Announces Grand Opening of Lewis Center, Ohio Store

Floor & Decor Announces Grand Opening of Beaverton, Oregon Store

Floor & Decor Holdings, Inc. Announces Appointment of Nada Aried to the Board of Directors

Comments

Floor & Decor Hldgs

매도 수량

Floor & Decor Hldgs (NYSE:FND) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌